KYMR · Company research

Kymera Therapeutics, Inc.

5 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

Trial resultsKYMRKymeraQ4 2026

Kymera expects to report results from its Phase 2b (enrollment complete) study of KT-621 (oral STAT6 degrader) for moderate-to-severe atopic dermatitis in Q4 2026 (Oct–Dec) (no exact date yet). This is the first look at whether the drug did what the company hoped.

More details

Entry

KT-621 BROADEN2 Phase 2b topline data in atopic dermatitis · Clinical trial results (readout / topline data)

Drug

KT-621 (oral STAT6 degrader)

For

moderate-to-severe atopic dermatitis

Stage

Phase 2b (enrollment complete)

When

Q4 2026 · the company gave a window, not a day

Source note

Enrollment completed ~6 months early; topline data accelerated to "by year-end 2026" from prior mid-2027 guidance. ~200 patients, three doses vs placebo, 16 weeks.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
KYMR headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsKYMRKymeraQ4 2026

Kymera expects to report results from its Phase 1 study of KT-579 (oral IRF5 degrader) for immunology (lupus and other autoimmune diseases) in Q4 2026 (Oct–Dec) (no exact date yet). Phase 1 is an early safety study in a small group of people.

More details

Entry

KT-579 Phase 1 healthy volunteer data · Clinical trial results (readout / topline data)

Drug

KT-579 (oral IRF5 degrader)

For

immunology (lupus and other autoimmune diseases)

Stage

Phase 1 · an early safety study in a small group of people

When

Q4 2026 · the company gave a window, not a day

Source note

Phase 1 healthy volunteer trial ongoing with data expected in 4Q26; Phase 1b lupus proof-of-concept trial planned soon after.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
KYMR headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneKYMRKymeraH1 2027

KT-621 Phase 3 initiation in atopic dermatitis, expected in the first half of 2027 (no exact date yet). A company milestone for Kymera (KT-621 (oral STAT6 degrader) for moderate-to-severe atopic dermatitis): a step in the program rather than a decision or a data readout.

More details

Entry

KT-621 Phase 3 initiation in atopic dermatitis · Company milestone

Drug

KT-621 (oral STAT6 degrader)

For

moderate-to-severe atopic dermatitis

Stage

Phase 3 · the last stage before a drug can be approved

When

H1 2027 · the company gave a window, not a day

Source note

Subject to regulator discussions, company expects to initiate Phase 3 AD trials by mid-2027.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
KYMR headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneKYMRKymera2027

Gilead IND filing for KT-200 CDK2 degrader, expected during 2027 (no exact date yet). A company milestone for Kymera (KT-200 for oncology (CDK2)): a step in the program rather than a decision or a data readout.

More details

Entry

Gilead IND filing for KT-200 CDK2 degrader · Company milestone

Drug

KT-200

For

oncology (CDK2)

Stage

Preclinical

When

2027 · the company gave a window, not a day

Source note

Q2 2026 PR (Aug 5, 2026): Gilead exercised its exclusive license option on KT-200 in April 2026 ($45M milestone) and plans an IND filing in 2027. Same PR reiterates KT-621 BROADEN2 AD data by year-end 2026, Ph3 AD start by mid-2027, BREADTH asthma data late 2027, and KT-579 Ph1 HV data in 4Q26 (all already tracked).

Checked

Checked by a person when it was added

Verify it

Source: manilatimes.net ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
KYMR headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsKYMRKymeraH2 2027

Kymera expects to report results from its Phase 2b study of KT-621 (oral STAT6 degrader) for asthma in the second half of 2027 (no exact date yet). This is the first look at whether the drug did what the company hoped.

More details

Entry

KT-621 BREADTH Phase 2b asthma data · Clinical trial results (readout / topline data)

Drug

KT-621 (oral STAT6 degrader)

For

asthma

Stage

Phase 2b

When

H2 2027 · the company gave a window, not a day

Source note

BREADTH Phase 2b asthma trial ongoing; data expected to be reported in late 2027.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
KYMR headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

MilestoneKYMRKymeraJun 25, 2026

BROADEN2 enrollment done early; KT-621 topline pulled forward to YE2026, on Jun 25, 2026. A company milestone for Kymera (KT-621 for moderate-to-severe atopic dermatitis): a step in the program rather than a decision or a data readout.

More details

Entry

BROADEN2 enrollment done early; KT-621 topline pulled forward to YE2026 · Company milestone

Drug

KT-621

For

moderate-to-severe atopic dermatitis

Stage

Phase 2b

When

Jun 25, 2026

Source note

Kymera completed enrollment in the global Phase 2b BROADEN2 trial of oral STAT6 degrader KT-621 in moderate-to-severe atopic dermatitis nearly six months early, accelerating topline data from mid-2027 to year-end 2026 and pulling Phase 3 starts into mid-2027.

Checked

Checked by a person when it was added

Verify it

Source: sec.gov ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
KYMR headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to KYMR.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.